Skip to main content
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2010 Jan 8;11(2):129–135. doi: 10.1007/s10194-009-0183-6

Long-term effects of a sensitisation campaign on migraine: the Casilino study

B Petolicchio 1, L Di Clemente 1, M Altieri 1, E Vicenzini 1, G L Lenzi 1, Vittorio Di Piero 1,
PMCID: PMC3452285  PMID: 20058047

Abstract

In 2003, we conducted a sensitisation campaign on migraine in the Casilino district of Rome, by sending a letter with the ID Migraine test to all the households and placing posters in the GPs’ waiting room. Out of 195 headache patients recruited, 92% had migraine while 73% had never consulted a physician for headache. The aim of this study was to evaluate the long-term impact of this campaign. The follow-up was performed by a telephone interview. The questionnaire considered the characteristics of headache, quality of life, preventive and acute treatments, drug efficacy, comorbidity and subjective usefulness of the campaign. Of the 179 migraineurs, 90.5% (mean age 40.7 ± 16.5, 139 females) were included in the follow-up. An improvement was observed in mean pain intensity (−13.9%; p < 0.0001) and mean HIT-6 score (−6.1%; p = 0.0003). The campaign was considered to be useful by 63.6% of cases, while 66.1% reported an improvement in their clinical status. Improved patients showed a decreased mean number of days with headache per month (−51.7%; p < 0.0001), pain intensity (−21.8%; p < 0.0001), headache duration (−18.1%; p = 0.0008) and HIT-6 score (−11.7%; p < 0.0001). Our data suggest that the effects of a “single shot” campaign are beneficial not only in a short-term perspective, but even in the long term. Moreover, the lack of benefit in more severe cases suggests that such patients should not be treated by GPs alone: patients in whom the HIT-6 score, frequency, severity or duration of headache worsen should be promptly referred to the headache clinic.

Keywords: Sensitisation campaign, Migraine, Follow-up, Disability

Full Text

The Full Text of this article is available as a PDF (172.9 KB).

Acknowledgments

Conflict of interest

None.

References

  • 1.Roncolato M, Fabbri L, Recchia G, Cavazzuti L, Visona G, Brignoli O, Medea G. An epidemiology study to assess migraine. Prevalence in a sample of italian population presenting to their GPs. Eur Neurol. 2000;43:102–106. doi: 10.1159/000008143. [DOI] [PubMed] [Google Scholar]
  • 2.Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58:885–894. doi: 10.1212/wnl.58.6.885. [DOI] [PubMed] [Google Scholar]
  • 3.Bigal ME, Lipton RB, Stewart WF. The epidemiology and impact of migraine. Curr Neurol Neurosci Rep. 2004;4:98–104. doi: 10.1007/s11910-004-0022-8. [DOI] [PubMed] [Google Scholar]
  • 4.Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF) J Headache Pain. 2005;6:429–440. doi: 10.1007/s10194-005-0252-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Steiner TJ. Lifting the burden: the global campaign to reduce the burden of headache worldwide. J Headache Pain. 2005;6:373–377. doi: 10.1007/s10194-005-0241-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Di Piero V, Altieri M, Conserva G, Petolicchio B, di Clemente L, Hettiarachchi J General Practitioner’s Co-operative of the Casilino district of Rome (2007) The effects of a sensitisation campaign on unrecognised migraine: the Casilino study. J Headache Pain 8:205–208 [DOI] [PMC free article] [PubMed]
  • 7.Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: the ID Migraine(TM) validation study. Neurology. 2003;61:375–382. doi: 10.1212/01.wnl.0000078940.53438.83. [DOI] [PubMed] [Google Scholar]
  • 8.Headache Classification Committee of the International Headache Society Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(Suppl 7):1–96. [PubMed] [Google Scholar]
  • 9.Lantéri-Minèt M, Auray JP, Hasnaoui A, Dartigues JF, Duru G, Henry P, Lucas C, Predalier A, Chazot G, Gaudin AF. Prevalence and description of chronic daily headache in the general population in France. Pain. 2003;102:143–149. doi: 10.1016/s0304-3959(02)00348-2. [DOI] [PubMed] [Google Scholar]
  • 10.Lipton RB, Stewart WF, Liberman J. Self-awareness of migraine. Interpreting the labels that headache sufferers apply to their headaches. Neurology. 2002;58(9 Suppl 6):S21–S26. doi: 10.1212/wnl.58.9_suppl_6.s21. [DOI] [PubMed] [Google Scholar]
  • 11.Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–657. doi: 10.1046/j.1526-4610.2001.041007646.x. [DOI] [PubMed] [Google Scholar]
  • 12.Lipton RB, Diamond S, Reed M, Diamond M, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41:638–645. doi: 10.1046/j.1526-4610.2001.041007638.x. [DOI] [PubMed] [Google Scholar]
  • 13.Sheftell FD, Tepper SJ, Bigal ME. Migraine: barriers for care. Neurol Sci. 2005;26:S140–S142. doi: 10.1007/s10072-005-0428-3. [DOI] [PubMed] [Google Scholar]
  • 14.Lipton RB, Bigal ME, Amatniek JC, Stewart WF. Tools for diagnosing for migraine measuring its severity. Headache. 2004;44:387–398. doi: 10.1111/j.1526-4610.2004.04089.x. [DOI] [PubMed] [Google Scholar]
  • 15.Martelletti P, Haimanot RT, Lainez MJ, Rapaport AM, Ravishankar K, Sakai F, Silberstein SD, Vincent M, Steiner TJ. The Global Campaign (GC) to reduce the burden of headache worldwide. The International Team for Specialist Education (ITSE) J Headache Pain. 2005;6:261–263. doi: 10.1007/s10194-005-0202-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Campinha-Bacote DL, Kendle JB, Jones C, Callicoat D, Webert A, Stoukides CA, Kaul AF. Impact of a migraine management on improving health outcomes. Dis Manag. 2005;8:382–391. doi: 10.1089/dis.2005.8.382. [DOI] [PubMed] [Google Scholar]
  • 17.Rothrock JF, Parada VA, Sims C, Key K, Walters NS, Zweifler RM. The impact of intensive patient education on clinical outcome in a clinic-based migraine-population. Headache. 2006;46:726–731. doi: 10.1111/j.1526-4610.2006.00428.x. [DOI] [PubMed] [Google Scholar]
  • 18.Blumenfeld A, Tischio M. Center of excellence for headache care: group model at Kaiser Permanente. Headache. 2003;43:431–440. doi: 10.1046/j.1526-4610.2003.03087.x. [DOI] [PubMed] [Google Scholar]
  • 19.Harpole L, Samsa G, Jurgelski AE, Shipley JL, Bernstein A, Matchar DB. Headache management program improves outcome for chronic headache. Headache. 2003;43:715–724. doi: 10.1046/j.1526-4610.2003.03128.x. [DOI] [PubMed] [Google Scholar]
  • 20.Karli N, Zarifoglu M, Erer S, Pala K, Akis N. The impact of education on the diagnostic accuracy of tension type headache and migraine: a prospective study. Cephalalgia. 2006;27:41–45. doi: 10.1111/j.1468-2982.2006.01245.x. [DOI] [PubMed] [Google Scholar]
  • 21.Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology. 1997;49:1219–1225. doi: 10.1212/wnl.49.5.1219. [DOI] [PubMed] [Google Scholar]
  • 22.Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19–26. doi: 10.1002/ana.10786. [DOI] [PubMed] [Google Scholar]
  • 23.Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol. 2004;55:27–36. doi: 10.1002/ana.10785. [DOI] [PubMed] [Google Scholar]
  • 24.Silberstein SD, Dodick D, Kesslick J. Removing barriers to appropriate migraine treatment: formulary limitations and triptan package size. Headache. 2005;45:1250–1254. doi: 10.1111/j.1526-4610.2005.00250.x. [DOI] [PubMed] [Google Scholar]
  • 25.Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans in migraine: detailed and methods of a meta-analysis pf 53 trial. Cephalalgia. 2002;22:633–658. doi: 10.1046/j.1468-2982.2002.00404.x. [DOI] [PubMed] [Google Scholar]
  • 26.Lucas C, Auray JP, Gaudin AF, Dartigues JF, Duru G, Henry P, Lantéri-Minet M, Pradalier A, Charzot G, El Hasnaoui A. Use and misuse of triptans in France: data from the GRIM 2000 population survey. Cephalalgia. 2004;24:197–205. doi: 10.1111/j.1468-2982.2003.00651.x. [DOI] [PubMed] [Google Scholar]
  • 27.Donnet A, Lantéri-Minèt M, Géraud G, Guegan-Massardier E, Demarquay G, Giraud P, Lucas C, Valade D. Impact of a public sensitization campaign on migraine management in France. J Headache Pain. 2009;10:241–247. doi: 10.1007/s10194-009-0128-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Panconesi A, Pavone E, Vacca F, Vaiani M, Banfi R. Triptans in the Italian population: a drug utilization and literature review. J Headache Pain. 2008;9:71–76. doi: 10.1007/s10194-008-0020-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Cevoli S, D’Amico D, Martelletti P, Valguarnera F, Del Bene E, Simone R, Sarchielli P, Narbone MC, Testa L, Genco S, Bussone G, Cortelli P. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia. 2009;29:1285–1293. doi: 10.1111/j.1468-2982.2009.01874.x. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES